167 related articles for article (PubMed ID: 37818555)
1. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
Li R; Jiang B; Zhu Y; Gao L; Zhou Y; Yang S
Endocr Metab Immune Disord Drug Targets; 2024; 24(5):606-610. PubMed ID: 37818555
[TBL] [Abstract][Full Text] [Related]
2. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
4. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports.
Shen X; Yang M; Xu H; Zhou H; Wang L; Ma J
Endocr Metab Immune Disord Drug Targets; 2023; 23(7):996-1004. PubMed ID: 36503448
[TBL] [Abstract][Full Text] [Related]
6. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
7. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
8. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related hypophysitis.
Mizukoshi T; Fukuoka H; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
[TBL] [Abstract][Full Text] [Related]
10. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
13. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features.
Esteves-Ferreira S; Rosinha P
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7925-7932. PubMed ID: 36869230
[TBL] [Abstract][Full Text] [Related]
15. The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature.
Urai S; Tomofuji S; Bando H; Kanzawa M; Yamamoto M; Fukuoka H; Tsuda M; Iguchi G; Ogawa W
J Neuroendocrinol; 2024 Jun; 36(6):e13395. PubMed ID: 38631695
[TBL] [Abstract][Full Text] [Related]
16. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
17. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
18. [A Case of Hypophysitis Due to Immune Check Point Inhibitor Treatment].
Natsuki S; Noda E; Iimori N; Okuno T; Kametani N; Tokumoto M; Kato Y; Yamada N; Nishimura S; Taenaka N
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2095-2097. PubMed ID: 33468812
[TBL] [Abstract][Full Text] [Related]
19. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
20. Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.
Amylidi AL; Gogadis A; Yerolatsite M; Zarkavelis G; Torounidou N; Keramisanou V; Kampletsas E; Mauri D
Curr Oncol; 2023 Dec; 30(12):10509-10518. PubMed ID: 38132400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]